PubMed Health⌕ Search

Biomedical subjects

Stephen Lockhart

Publications and source records attributed to Stephen Lockhart.

3 recordsLinked to original sources

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.

BACKGROUND & AIMS: Evidence suggests that postprandial platelet-depleted plasma 5-hydroxytryptamine (5-HT) concentrations may be abnormal in irritable bowel syndrome (IBS). However, interpretation of the data has been hampered by the variable methodology and rather small numbers used in previous studies. Therefore, the aim of this study was to measure concentrations of platelet-depleted plasma 5-HT and its metabolite 5-HIAA under fasting and fed conditions in a large group of patients with diarrhea-predominant (d-) and constipation-predominant (c-) IBS, compared with controls. The ratio of plasma 5-HIAA:5-HT and platelet stores was also assessed. METHODS: Twenty-nine c-IBS patients (aged, 19-53 years), 55 d-IBS patients (aged, 19-52 years), and 35 healthy volunteers (aged, 18-46 years) had platelet-depleted plasma 5-HT/5-HIAA concentrations measured using reverse-phase, high-performance liquid chromatography with fluorimetric detection before and after a standard meal. RESULTS: d-IBS patients had raised platelet-depleted plasma 5-HT concentrations under fasting and fed conditions (P < .05). However, the postprandial relative to fasting concentration was similar to controls. In contrast, c-IBS patients failed to show an increase in platelet-depleted plasma 5-HT concentration with meal ingestion compared with controls (P < .01). c-IBS was associated with decreased 5-HIAA (P < .01) but normal 5-HIAA:5-HT ratio and d-IBS with normal 5-HIAA concentrations but reduced 5-HIAA:5-HT ratio (P < .005). C-IBS but not d-IBS patients had increased platelet 5-HT. CONCLUSIONS: These results support the concept that d-IBS is characterized by reduced 5-HT reuptake, whereas impaired release may be a feature of c-IBS. These results also provide a rational basis for current pharmacologic approaches involving modulation of different 5-HT receptors in c- and d-IBS.

Adult↗

Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry.

A simple and rapid liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method for the analysis of voriconazole has been developed. For comparison, serum voriconazole was measured using HPLC and bioassay. For the HPLC-MS/MS assay, samples were prepared in a deep-well block by adding 10 microL of serum to 40 microL of 0.1 M zinc sulfate solution. Proteins were precipitated by adding 100 microL acetonitrile containing ketoconazole as internal standard. After vigorous mixing and centrifugation, 3 microL of the supernatant was injected into the HPLC-MS/MS system. An HPLC system was used to elute a C18 cartridge (2 mm x 4 mm) at 0.6 mL/min with a step gradient of 50% to 100% methanol containing 2 mM ammonium acetate and 0.1% (vol/vol) formic acid. The column was maintained at 55 degrees C, and the retention times were voriconazole 1.50 minutes and ketoconazole 1.47 minutes. Cycle time was 3 minutes, injection to injection. The analytes were monitored using a tandem mass spectrometer operated in multiple reaction monitoring mode using the following transitions: voriconazole m/z 350.0 > 224.1 and ketoconazole m/z 531.1 > 489.1. Within- and between-batch CVs were < 5% and < 8%, respectively, over the range 0.38 to 15.3 mg/L. The lower limit of quantification was 0.1 mg/L. Regression analysis showed HPLC-MS/MS = 1.06 +/- 0.02 (HPLC-UV) - 0.07 +/- 0.1, R2 = 0.95, n = 99.

Chromatography, High Pressure Liquid↗

Conjugate vaccines.

Conjugate vaccines in which the capsular polysaccharide of Haemophilus influenzae type b, common serotypes of Streptococcus pneumoniae and group C Neisseria meningitidis are covalently bound to a protein antigen to convert a T-cell-independent immune response into a T-cell-dependent response have proved highly effective in the prevention of invasive disease in infants and young children. This review looks at what has been learnt from developing these vaccines that could be useful for the clinical development of future conjugate vaccines, in such areas as combination vaccines, dose-ranging, cross-protection of closely related antigens, prevention of noninvasive disease, correlates of protection and use in older age groups. In addition, a wide range of other organisms may be susceptible to conjugate vaccines and new indications and approaches are considered. This will be a highly active area for many years to come.

Child↗